← All indications
Adenomatous Polyposis Coli
A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.
Subtype terms (1)
More specific conditions that are subtypes of Adenomatous Polyposis Coli in the MeSH hierarchy.
Drugs by status
Phase 4 trials (2)
Phase 2 trials (21)
Phase 1 trials (7)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (15)
- Axcan
- Pfizer
- Cancer Prevention Pharmaceuticals, Inc.
- National Cancer Institute (NCI)
- University of London
- Pierre and Marie Curie University
- Radboud University
- University of Hamburg
- University of Rochester
- University of Bologna
- University of Utah
- SLA Pharma
- University of Paris
- Dutch Cancer Society
- People's Liberation Army of China
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (2)